<p>Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis</p>

Background: Atopic dermatitis is a chronic, relapsing and remitting disease that can be difficult to treat despite a recently approved biologic therapy targeting IL-4/IL-13 receptor. Oral janus kinase inhibitors (JAKi) represent a novel therapeutic class of targeted therapy to treat moderate-to-severe atopic dermatitis (AD).Objective: To review the efficacy, safety, and pharmacokinetic characteristics of oral JAKi in the treatment of AD.Methods: A PRISMA systematic review was conducted using MEDLINE, EMBASE (Ovid), and PubMed databases for studies assessing the efficacy, safety, and/or pharmacokinetic properties of oral forms of JAKi in the treatment of AD in pediatric or adult populations from inception to June 2021.Results: 496 papers were reviewed. Of 28 articles that underwent full text screening, 11 met our inclusion criteria for final qualitative review. Four studies examined abrocitinib; three studies examined baricitinib; three examined upadacitinib and one examined gusacitinib (ASN002). Significant clinical efficacy and a reassuring safety profile was reported for all JAKi agents reviewed. Rapid symptom control was reported for abrocitinib, baricitinib and upadacitinib.Limitations: Given the relatively limited evidence for each JAKi and the differences in patient eligibility criteria between studies, the data was not deemed suitable for a meta-analysis at this time.Conclusion: Given their ability to achieve rapid symptom control with a reassuring safety profile, we recommend considering the use of JAKi as a reliable systemic treatment option for adult patients with moderate-to-severe AD, who are unresponsive to topical or skin directed treatments.

Download Full-text

Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo

Mini-Reviews in Medicinal Chemistry ◽

10.2174/1389557521666210325120233 ◽

2021 ◽

Vol 21 ◽

Author(s):

Chao Niu ◽

Hunjun Xie ◽

Haji Akber Aisa

Keyword(s):

Cell Proliferation ◽

Atopic Dermatitis ◽

Immune System ◽

Immune Regulation ◽

Kinase Inhibitors ◽

Janus Kinase ◽

Jak Inhibitors ◽

Janus Kinase Inhibitors ◽

Small Molecular Inhibitors ◽

Stat Pathway

: The small-molecular inhibitors targeted JAks (JAK inhibitors), could modulate the cytokines-mediated signaling via JAK-STAT pathway, which plays a important role in immune regulation and cell proliferation. The JAK inhibitors are previously designed and synthesized to treat diseases involved with hematologic and immune system. Increasing evidence shows that they are quite effective in atopic dermatitis (AD), alopecia areata (AA), psoriasis, vitiligo, and other autoimmune-induced dermatologic conditions. Currently, many JAK inhibitors possessing anti-vitiligo activity are being investigated in laboratory and clinically. In this view, we would like to summarize so we review the applications of these inhibitors with emphasis on profile of vitiligo, clinical efficacy, dosages, development of new candidates and adverse events through available literatures.

Download Full-text

Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications

The Journal of Dermatology ◽

10.1111/1346-8138.16116 ◽

2021 ◽

Author(s):

Po‐Hsiung Chang ◽

Sheng‐Fen Huang ◽

Po‐Sheng Chang ◽

Yu Yu

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitors ◽

Janus Kinase ◽

Janus Kinase Inhibitors ◽

Safety Considerations

Download Full-text

Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses

Actas Dermo-Sifiliográficas (English Edition) ◽

10.1016/j.adengl.2021.05.008 ◽

2021 ◽

Author(s):

C. García-Melendo ◽

X. Cubiró ◽

L. Puig

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitors ◽

Janus Kinase ◽

Janus Kinase Inhibitors

Download Full-text

Role of Janus Kinase Inhibitors in Therapy of Psoriasis

Journal of Clinical Medicine ◽

10.3390/jcm10194307 ◽

2021 ◽

Vol 10 (19) ◽

pp. 4307

Author(s):

Sylwia Słuczanowska-Głąbowska ◽

Anna Ziegler-Krawczyk ◽

Kamila Szumilas ◽

Andrzej Pawlik

Keyword(s):

Side Effects ◽

First Generation ◽

Kinase Inhibitors ◽

Janus Kinase ◽

Jak Inhibitors ◽

Biologic Drugs ◽

Janus Kinases ◽

Janus Kinase Inhibitors ◽

Long Term Treatment

Janus kinases inhibitors are molecules that target Janus kinases—signal transducers and activators of transcription (JAK/STAT). They inhibit this intracellular signal pathway, blocking the gene transcription of crucial proinflammatory cytokines that play a central role in the pathogenesis of many inflammatory and autoimmune diseases, including psoriasis. This process reduces psoriatic inflammation. The JAK inhibitors are divided into two generations. The first generation of JAK inhibitors blocks two or more different Janus kinases. The second generation is more specified and blocks only one type of Janus kinase and has less side effects than the first generation. Tofacitinib, ruxolitinib and baricitinib belong to first generation JAK inhibitors and decernotinib and filgotinib belong to second group. This narrative review summarizes the role of Janus kinase inhibitors in the therapy of psoriasis. Oral JAK inhibitors show promise for efficacy and safety in the treatment of psoriasis. Studies to date do not indicate that JAK inhibitors are superior to recent biologic drugs in terms of efficacy. However, JAK inhibitors, due to their lack of increased incidence of side effects compared to other biologic drugs, can be included in the psoriasis treatment algorithm because they are orally taken. Nevertheless, further studies are needed to evaluate long-term treatment effects with these drugs.

Download Full-text